Union Bancaire Privee UBP SA Boosts Stock Position in Regeneron Pharmaceuticals, Inc. $REGN

Union Bancaire Privee UBP SA lifted its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 672.3% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 3,993 shares of the biopharmaceutical company’s stock after acquiring an additional 3,476 shares during the quarter. Union Bancaire Privee UBP SA’s holdings in Regeneron Pharmaceuticals were worth $3,019,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in REGN. Salomon & Ludwin LLC bought a new position in shares of Regeneron Pharmaceuticals in the third quarter worth approximately $27,000. Migdal Insurance & Financial Holdings Ltd. bought a new stake in shares of Regeneron Pharmaceuticals during the 2nd quarter valued at $31,000. Caitlin John LLC purchased a new position in shares of Regeneron Pharmaceuticals during the 3rd quarter valued at $34,000. Traub Capital Management LLC purchased a new position in shares of Regeneron Pharmaceuticals during the 2nd quarter valued at $38,000. Finally, Berbice Capital Management LLC boosted its holdings in Regeneron Pharmaceuticals by 300.0% in the 2nd quarter. Berbice Capital Management LLC now owns 80 shares of the biopharmaceutical company’s stock worth $42,000 after buying an additional 60 shares during the period. Institutional investors own 83.31% of the company’s stock.

Insider Activity

In other news, Director Huda Y. Zoghbi sold 1,638 shares of the stock in a transaction on Thursday, February 19th. The shares were sold at an average price of $781.33, for a total value of $1,279,818.54. Following the sale, the director owned 1,703 shares of the company’s stock, valued at approximately $1,330,604.99. This represents a 49.03% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, SVP Jason Pitofsky sold 2,036 shares of the firm’s stock in a transaction dated Monday, February 9th. The stock was sold at an average price of $778.52, for a total transaction of $1,585,066.72. Following the completion of the sale, the senior vice president owned 4,272 shares of the company’s stock, valued at $3,325,837.44. This trade represents a 32.28% decrease in their position. The SEC filing for this sale provides additional information. Over the last three months, insiders have sold 5,274 shares of company stock worth $4,142,738. 7.02% of the stock is currently owned by insiders.

Regeneron Pharmaceuticals Trading Down 0.6%

Shares of NASDAQ REGN opened at $732.87 on Friday. Regeneron Pharmaceuticals, Inc. has a 1-year low of $476.49 and a 1-year high of $821.11. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.13 and a quick ratio of 3.39. The business’s 50 day moving average is $765.35 and its two-hundred day moving average is $699.83. The stock has a market capitalization of $77.48 billion, a P/E ratio of 17.63, a PEG ratio of 1.98 and a beta of 0.41.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings data on Friday, January 30th. The biopharmaceutical company reported $11.44 earnings per share (EPS) for the quarter, beating the consensus estimate of $10.74 by $0.70. The business had revenue of $3.88 billion during the quarter, compared to analyst estimates of $3.76 billion. Regeneron Pharmaceuticals had a return on equity of 13.04% and a net margin of 31.41%.The company’s revenue for the quarter was up 2.5% on a year-over-year basis. During the same period last year, the company earned $12.07 EPS. As a group, research analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Thursday, March 5th. Shareholders of record on Friday, February 20th were paid a dividend of $0.94 per share. The ex-dividend date of this dividend was Friday, February 20th. This is a positive change from Regeneron Pharmaceuticals’s previous quarterly dividend of $0.88. This represents a $3.76 annualized dividend and a yield of 0.5%. Regeneron Pharmaceuticals’s payout ratio is presently 9.05%.

Wall Street Analyst Weigh In

A number of research firms have commented on REGN. Barclays initiated coverage on Regeneron Pharmaceuticals in a report on Friday, March 6th. They set an “overweight” rating and a $923.00 price target on the stock. Wall Street Zen lowered Regeneron Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Sunday, March 8th. JPMorgan Chase & Co. increased their target price on Regeneron Pharmaceuticals from $850.00 to $950.00 and gave the stock an “overweight” rating in a research report on Monday, February 2nd. Scotiabank boosted their price target on Regeneron Pharmaceuticals from $650.00 to $770.00 and gave the stock a “sector perform” rating in a report on Monday, November 24th. Finally, Morgan Stanley boosted their price target on shares of Regeneron Pharmaceuticals from $768.00 to $769.00 and gave the stock an “equal weight” rating in a research note on Monday, February 2nd. Two research analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and nine have given a Hold rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $802.27.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.